Mabanta S R, Buatti J M, Friedman W A, Meeks S L, Mendenhall W M, Bova F J
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, USA.
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):545-8. doi: 10.1016/s0360-3016(98)00445-3.
To analyze the results of nonacoustic schwannomas treated with linear accelerator stereotactic radiosurgery.
Between August 1989 and October 1997, 18 patients with nonacoustic schwannomas underwent stereotactic radiosurgery at the University of Florida. Nine patients had schwannomas located in the jugular foramen region, seven in the trigeminal nerve, and two in the facial nerve. Nine patients had initial subtotal resections and nine did not undergo surgical intervention. One of the 9 patients with subtotal resection was treated with radiosurgery for a recurrent tumor. Tumor volumes ranged from 0.7 to 15.4 cm3 with a mean volume of 5.5 cm3. Minimal tumor doses ranged from 10.0 to 15.0 Gy with a mean dose of 13.1 Gy. Treatment dose was specified to the 80% isodose shell in 11 patients (58%) and to the 70% isodose shell in the remaining patients. Ten patients (56%) were treated with a single isocenter, 6 patients (33%) with 2-4 isocenters, and 2 patients (11%) with greater than 5 isocenters. Follow-up ranged from 5 to75 months and the mean follow-up was 32 months. Ten patients (56%) had follow-up beyond 2 years and none were lost to follow-up. Local control was defined as clinically stable neurological status and/or stable or decreased tumor size on yearly follow-up MR imaging.
Eighteen evaluable patients (100%) had local control after treatment. All were alive and progression-free at last follow-up. Six of 10 patients with follow-up MRI 2 years or more after treatment had tumor regression and 4 patients had stable disease. Three additional patients with an MRI at 1 year showed no tumor change. Four complications in 3 patients included one worsening of a preexisting VII nerve palsy, 2 patients with new onset of hearing loss, and one with ataxia. No surgical intervention or prolonged steroid use was necessary for any patient with complications. Five patients had improvement in preexisting neurologic deficits.
Excellent preliminary tumor control rates and a favorable toxicity profile support the effectiveness of linear accelerator stereotactic radiosurgery for patients with nonacoustic schwannomas.
分析用直线加速器立体定向放射外科治疗非听神经鞘瘤的结果。
1989年8月至1997年10月期间,18例非听神经鞘瘤患者在佛罗里达大学接受了立体定向放射外科治疗。9例患者的神经鞘瘤位于颈静脉孔区,7例位于三叉神经,2例位于面神经。9例患者最初接受了次全切除,9例未接受手术干预。9例次全切除患者中的1例因肿瘤复发接受了放射外科治疗。肿瘤体积为0.7至15.4 cm³,平均体积为5.5 cm³。最小肿瘤剂量为10.0至15.0 Gy,平均剂量为13.1 Gy。11例患者(58%)的治疗剂量指定到80%等剂量线,其余患者指定到70%等剂量线。10例患者(56%)采用单个等中心治疗,6例患者(33%)采用2 - 4个等中心治疗,2例患者(11%)采用超过5个等中心治疗。随访时间为5至75个月,平均随访时间为32个月。10例患者(56%)的随访时间超过2年,无一例失访。局部控制定义为临床神经状态稳定和/或每年随访磁共振成像显示肿瘤大小稳定或缩小。
18例可评估患者(100%)治疗后实现了局部控制。所有患者在最后一次随访时均存活且无疾病进展。10例治疗后随访磁共振成像2年或更长时间的患者中,6例肿瘤缩小,4例病情稳定。另外3例在1年时进行磁共振成像检查的患者显示肿瘤无变化。3例患者出现4例并发症,包括1例原有VII神经麻痹加重,2例新发听力丧失,1例共济失调。对于任何有并发症的患者,均无需进行手术干预或长期使用类固醇。5例患者原有神经功能缺损有所改善。
良好的初步肿瘤控制率和良好的毒性特征支持直线加速器立体定向放射外科治疗非听神经鞘瘤患者的有效性。